Cargando…
Cardiac MRI Endpoints in Myocardial Infarction Experimental and Clinical Trials: JACC Scientific Expert Panel
After a reperfused myocardial infarction (MI), dynamic tissue changes occur (edema, inflammation, microvascular obstruction, hemorrhage, cardiomyocyte necrosis, and ultimately replacement by fibrosis). The extension and magnitude of these changes contribute to long-term prognosis after MI. Cardiac m...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7363031/ https://www.ncbi.nlm.nih.gov/pubmed/31296297 http://dx.doi.org/10.1016/j.jacc.2019.05.024 |
_version_ | 1783559597412319232 |
---|---|
author | Ibanez, Borja Aletras, Anthony H. Arai, Andrew E. Arheden, Hakan Bax, Jeroen Berry, Colin Bucciarelli-Ducci, Chiara Croisille, Pierre Dall’Armellina, Erica Dharmakumar, Rohan Eitel, Ingo Fernández-Jiménez, Rodrigo Friedrich, Matthias G. García-Dorado, David Hausenloy, Derek J. Kim, Raymond J. Kozerke, Sebastian Kramer, Christopher M. Salerno, Michael Sánchez-González, Javier Sanz, Javier Fuster, Valentin |
author_facet | Ibanez, Borja Aletras, Anthony H. Arai, Andrew E. Arheden, Hakan Bax, Jeroen Berry, Colin Bucciarelli-Ducci, Chiara Croisille, Pierre Dall’Armellina, Erica Dharmakumar, Rohan Eitel, Ingo Fernández-Jiménez, Rodrigo Friedrich, Matthias G. García-Dorado, David Hausenloy, Derek J. Kim, Raymond J. Kozerke, Sebastian Kramer, Christopher M. Salerno, Michael Sánchez-González, Javier Sanz, Javier Fuster, Valentin |
author_sort | Ibanez, Borja |
collection | PubMed |
description | After a reperfused myocardial infarction (MI), dynamic tissue changes occur (edema, inflammation, microvascular obstruction, hemorrhage, cardiomyocyte necrosis, and ultimately replacement by fibrosis). The extension and magnitude of these changes contribute to long-term prognosis after MI. Cardiac magnetic resonance (CMR) is the gold-standard technique for noninvasive myocardial tissue characterization. CMR is also the preferred methodology for the identification of potential benefits associated with new cardioprotective strategies both in experimental and clinical trials. However, there is a wide heterogeneity in CMR methodologies used in experimental and clinical trials, including time of post-MI scan, acquisition protocols, and, more importantly, selection of endpoints. There is a need for standardization of these methodologies to improve the translation into a real clinical benefit. The main objective of this scientific expert panel consensus document is to provide recommendations for CMR endpoint selection in experimental and clinical trials based on pathophysiology and its association with hard outcomes. |
format | Online Article Text |
id | pubmed-7363031 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
record_format | MEDLINE/PubMed |
spelling | pubmed-73630312020-07-15 Cardiac MRI Endpoints in Myocardial Infarction Experimental and Clinical Trials: JACC Scientific Expert Panel Ibanez, Borja Aletras, Anthony H. Arai, Andrew E. Arheden, Hakan Bax, Jeroen Berry, Colin Bucciarelli-Ducci, Chiara Croisille, Pierre Dall’Armellina, Erica Dharmakumar, Rohan Eitel, Ingo Fernández-Jiménez, Rodrigo Friedrich, Matthias G. García-Dorado, David Hausenloy, Derek J. Kim, Raymond J. Kozerke, Sebastian Kramer, Christopher M. Salerno, Michael Sánchez-González, Javier Sanz, Javier Fuster, Valentin J Am Coll Cardiol Article After a reperfused myocardial infarction (MI), dynamic tissue changes occur (edema, inflammation, microvascular obstruction, hemorrhage, cardiomyocyte necrosis, and ultimately replacement by fibrosis). The extension and magnitude of these changes contribute to long-term prognosis after MI. Cardiac magnetic resonance (CMR) is the gold-standard technique for noninvasive myocardial tissue characterization. CMR is also the preferred methodology for the identification of potential benefits associated with new cardioprotective strategies both in experimental and clinical trials. However, there is a wide heterogeneity in CMR methodologies used in experimental and clinical trials, including time of post-MI scan, acquisition protocols, and, more importantly, selection of endpoints. There is a need for standardization of these methodologies to improve the translation into a real clinical benefit. The main objective of this scientific expert panel consensus document is to provide recommendations for CMR endpoint selection in experimental and clinical trials based on pathophysiology and its association with hard outcomes. 2019-07-16 /pmc/articles/PMC7363031/ /pubmed/31296297 http://dx.doi.org/10.1016/j.jacc.2019.05.024 Text en This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Article Ibanez, Borja Aletras, Anthony H. Arai, Andrew E. Arheden, Hakan Bax, Jeroen Berry, Colin Bucciarelli-Ducci, Chiara Croisille, Pierre Dall’Armellina, Erica Dharmakumar, Rohan Eitel, Ingo Fernández-Jiménez, Rodrigo Friedrich, Matthias G. García-Dorado, David Hausenloy, Derek J. Kim, Raymond J. Kozerke, Sebastian Kramer, Christopher M. Salerno, Michael Sánchez-González, Javier Sanz, Javier Fuster, Valentin Cardiac MRI Endpoints in Myocardial Infarction Experimental and Clinical Trials: JACC Scientific Expert Panel |
title | Cardiac MRI Endpoints in Myocardial Infarction Experimental and Clinical Trials: JACC Scientific Expert Panel |
title_full | Cardiac MRI Endpoints in Myocardial Infarction Experimental and Clinical Trials: JACC Scientific Expert Panel |
title_fullStr | Cardiac MRI Endpoints in Myocardial Infarction Experimental and Clinical Trials: JACC Scientific Expert Panel |
title_full_unstemmed | Cardiac MRI Endpoints in Myocardial Infarction Experimental and Clinical Trials: JACC Scientific Expert Panel |
title_short | Cardiac MRI Endpoints in Myocardial Infarction Experimental and Clinical Trials: JACC Scientific Expert Panel |
title_sort | cardiac mri endpoints in myocardial infarction experimental and clinical trials: jacc scientific expert panel |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7363031/ https://www.ncbi.nlm.nih.gov/pubmed/31296297 http://dx.doi.org/10.1016/j.jacc.2019.05.024 |
work_keys_str_mv | AT ibanezborja cardiacmriendpointsinmyocardialinfarctionexperimentalandclinicaltrialsjaccscientificexpertpanel AT aletrasanthonyh cardiacmriendpointsinmyocardialinfarctionexperimentalandclinicaltrialsjaccscientificexpertpanel AT araiandrewe cardiacmriendpointsinmyocardialinfarctionexperimentalandclinicaltrialsjaccscientificexpertpanel AT arhedenhakan cardiacmriendpointsinmyocardialinfarctionexperimentalandclinicaltrialsjaccscientificexpertpanel AT baxjeroen cardiacmriendpointsinmyocardialinfarctionexperimentalandclinicaltrialsjaccscientificexpertpanel AT berrycolin cardiacmriendpointsinmyocardialinfarctionexperimentalandclinicaltrialsjaccscientificexpertpanel AT bucciarelliduccichiara cardiacmriendpointsinmyocardialinfarctionexperimentalandclinicaltrialsjaccscientificexpertpanel AT croisillepierre cardiacmriendpointsinmyocardialinfarctionexperimentalandclinicaltrialsjaccscientificexpertpanel AT dallarmellinaerica cardiacmriendpointsinmyocardialinfarctionexperimentalandclinicaltrialsjaccscientificexpertpanel AT dharmakumarrohan cardiacmriendpointsinmyocardialinfarctionexperimentalandclinicaltrialsjaccscientificexpertpanel AT eitelingo cardiacmriendpointsinmyocardialinfarctionexperimentalandclinicaltrialsjaccscientificexpertpanel AT fernandezjimenezrodrigo cardiacmriendpointsinmyocardialinfarctionexperimentalandclinicaltrialsjaccscientificexpertpanel AT friedrichmatthiasg cardiacmriendpointsinmyocardialinfarctionexperimentalandclinicaltrialsjaccscientificexpertpanel AT garciadoradodavid cardiacmriendpointsinmyocardialinfarctionexperimentalandclinicaltrialsjaccscientificexpertpanel AT hausenloyderekj cardiacmriendpointsinmyocardialinfarctionexperimentalandclinicaltrialsjaccscientificexpertpanel AT kimraymondj cardiacmriendpointsinmyocardialinfarctionexperimentalandclinicaltrialsjaccscientificexpertpanel AT kozerkesebastian cardiacmriendpointsinmyocardialinfarctionexperimentalandclinicaltrialsjaccscientificexpertpanel AT kramerchristopherm cardiacmriendpointsinmyocardialinfarctionexperimentalandclinicaltrialsjaccscientificexpertpanel AT salernomichael cardiacmriendpointsinmyocardialinfarctionexperimentalandclinicaltrialsjaccscientificexpertpanel AT sanchezgonzalezjavier cardiacmriendpointsinmyocardialinfarctionexperimentalandclinicaltrialsjaccscientificexpertpanel AT sanzjavier cardiacmriendpointsinmyocardialinfarctionexperimentalandclinicaltrialsjaccscientificexpertpanel AT fustervalentin cardiacmriendpointsinmyocardialinfarctionexperimentalandclinicaltrialsjaccscientificexpertpanel |